Response and specific function of IFN-lambda3 against infectious diseases

我们最近建立了一种由IL28B基因编码的干扰素-lambda3蛋白的检测方法，用于预测聚乙二醇化干扰素和利巴韦林(Peg-干扰素/RBV)治疗慢性丙型肝炎的疗效。结果表明，用Toll样受体7激动剂刺激的单个核细胞培养上清液中的干扰素-lambda3水平或血清中的干扰素-lambda3水平能更好地预测Peg-干扰素/RBV治疗的疗效，而不是IL28B的遗传变异。我们还证实了人BDCA3+树突状细胞识别丙型肝炎病毒，并通过Toll样受体3途径产生干扰素-lambda3。

We have newly developed a detection assay for IFN-lambda3 protein, being encoded by IL28B gene that predict the efficacy of pegylated interferon and ribavirin (Peg-IFN/RBV) therapy for chronic hepatitis C patients. Using this assay, we demonstrated that IFN-lambda3 levels in the supernatant of peripheral mononuclear cells stimulated with toll-like receptor 7 agonist or serum levels of IFN-lambda3 more favorably predict the efficay of Peg-IFN/RBV treatment rather than genetic variation of IL28B. We also demonstrated that human BDCA3+dendritic cells recognize hepatitis C virus and produce IFN-lambda3 through toll-like receptor 3 pathway.